Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
87 studies found for:    agitation and alzheimer's
Show Display Options
Rank Status Study
1 Completed
Has Results
Citalopram for Agitation in Alzheimer's Disease
Conditions: Alzheimer's Disease;   Agitation
Interventions: Drug: citalopram;   Drug: placebo
2 Completed The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease
Conditions: Alzheimer's Disease;   Agitation
Intervention:
3 Completed Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY451395;   Drug: Placebo
4 Recruiting Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Drug: AVP-786;   Drug: Placebo
5 Recruiting Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Drug: AVP-786;   Drug: Placebo
6 Unknown  Memantine on Aggression and Agitation of Alzheimer's Disease (AD)
Condition: Alzheimer's Disease
Intervention: Drug: Memantine
7 Recruiting ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
Condition: Agitation in Dementia, Including Alzheimer's Disease
Interventions: Drug: ITI-007;   Drug: Placebo
8 Completed
Has Results
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: ELND005;   Drug: Placebo
9 Completed
Has Results
Alzheimer's in Long-Term Care--Treatment for Agitation
Conditions: Alzheimer Disease;   Psychomotor Agitation
Interventions: Drug: prazosin;   Drug: placebo (inert substance)
10 Completed Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Conditions: Agitation;   Alzheimer's Disease
Interventions: Drug: AVP-923 (dextromethorphan/quinidine);   Drug: Placebo
11 Not yet recruiting Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD)
Condition: Alzheimer's Disease
Interventions: Drug: Dronabinol (Marinol®);   Drug: Placebo
12 Recruiting Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: ORM-12741;   Drug: Placebo
13 Recruiting Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Condition: Agitation Associated With Dementia of the Alzheimer's Type
Interventions: Drug: 2 mg/day;   Drug: 3 mg/day;   Drug: 6 mg/day;   Drug: Placebo (0 mg/day)
14 Completed Effects of Light-therapy in Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Other: Luxtherapy
15 Recruiting A Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Conditions: Agitation Associated With;   Alzheimer's Disease;   Alzheimer's Type;   Mental Disorder;   Nervous System Diseases
Intervention: Drug: Brexpiprazole, OPC-34712
16 Recruiting Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Conditions: Agitation Associated With;   Alzheimer's Disease;   Alzheimer's Type;   Mental Disorder;   Nervous System Diseases
Intervention: Drug: Brexpiprazole, OPC-34712
17 Completed An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: memantine HCl
18 Recruiting Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Alzheimer's Disease
Intervention: Drug: AVP-786
19 Terminated
Has Results
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Group 1 ELND005;   Drug: Group 2 ELND005
20 Completed Specific Interventions for Agitation in Alzheimer's Disease
Conditions: Alzheimer's Disease;   Dementia
Interventions: Drug: Risperidone;   Drug: Gabapentin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.